Emergence of Zaire Ebola virus disease in Guinea-preliminary report, N Engl J Med, vol.371, pp.1418-1425, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01011799
DOI : 10.1056/NEJMoa1404505
Nomenclature-and database-compatible names for the two Ebola virus variants that emerged in Guinea and the Democratic Republic of the Congo in 2014, Viruses, vol.6, p.25421896, 2014. ,
DOI : 10.3390/v6114760
, World Health Organization. Ebola virus disease (EVD) in West Africa: an extraordinary epidemic, Wkly Epidemiol Rec, vol.90, pp.89-96, 2015.
Human asymptomatic Ebola infection and strong inflammatory response, Lancet, vol.355, p.10881895, 2000. ,
Ebola haemorrhagic fever, Lancet, vol.377, issue.10, p.21084112, 2011. ,
Clinical presentation and management of severe Ebola virus disease, Ann Am Thorac Soc, vol.11, 2014. ,
Clinical illness and outcomes in patients with Ebola in Sierra Leone, N Engl J Med, vol.371, pp.2092-2100, 2014. ,
Ebola virus disease: experience and decision making for the first patients outside of Africa, PLoS Med, vol.12, p.1001857, 2015. ,
Clinical care of two patients with Ebola virus disease in the United States, N Engl J Med, vol.371, pp.2402-2409, 2014. ,
DOI : 10.1056/NEJMoa1409838
Acute respiratory distress syndrome after convalescent plasma use: treatment of a patient with Ebola virus disease, Lancet Respir Med, vol.3, pp.554-562, 2015. ,
DOI : 10.1016/s2213-2600(15)00180-0
, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola, 2015.
Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, pp.153-155, 2014. ,
Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Res, vol.100, p.24084488, 2013. ,
In vitro and in vivo activities of anti-influenza virus compound T-705, Antimicrob Agents Chemother, vol.46, pp.977-981, 2002. ,
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, p.24583123, 2014. ,
Phase 3 efficacy and safety study of favipiravir for treatment of uncomplicated influenza in Adults, ClinicalTrials.gov, 2013. ,
Ebola virus dynamics in mice treated with favipiravir, Antiviral Res, vol.123, pp.70-77, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01196078
Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, pp.150-151, 2014. ,
Favipiravir for children with Ebola, Lancet, vol.385, pp.603-604, 2015. ,
Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, J Infect Dis, vol.179, p.9988162, 1999. ,
Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, J Infect Dis, vol.179, p.9988182, 1995. ,
Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome, J Virol, vol.78, p.15047846, 2004. ,
Ebola virus disease: focus on children, Pediatr Infect Dis J, vol.34, p.25831417, 2015. ,
Blood chemistry measurements and D-dimer levels associated with fatal and nonfatal outcomes in humans infected with Sudan Ebola virus, J Infect, vol.196, pp.364-71, 2007. ,
Basic clinical and laboratory features of filoviral hemorrhagic fever, J Infect Dis, vol.204, p.21987756, 2011. ,
Clinical presentation of patients with Ebola virus disease in Conakry, Guinea, N Engl J Med, vol.372, pp.40-47, 2015. ,
, Ebola in West Africa-Guinea: resistance to the Ebola response. ACAPS Thematic Note, ACAPS, 2015.
Reaching out to Ebola victims: coercion, persuasion or an appeal for self-sacrifice?, Soc Sci Med, vol.147, pp.126-133, 2015. ,
, Presidential Commission for the Study of Bioethical Issues. Ethics and Ebola: public health planning and response, 2015.
Rapid detection of filoviruses by real-time TaqMan polymerase chain reaction assays, Virol Sin, vol.27, pp.273-277, 2012. ,
Participants understanding of informed consent in clinical trials over three decades: systematic review and meta-analysis, Bull World Health Organ, vol.93, pp.186-198, 2015. ,
The design and analysis of sequential clinical trials, 1997. ,
Two-sided confidence intervals for the single proportion: comparison of seven methods, Stat Med, vol.17, p.9595616, 1998. ,
Multivariate or multivariable regression, Am J Public Health, vol.103, p.23153131, 2013. ,
DOI : 10.2105/ajph.2012.300897
URL : http://europepmc.org/articles/pmc3518362?pdf=render
Plotting p against x, Appl Stat, vol.32, pp.25-31, 1983. ,
DOI : 10.2307/2348040
, Favipiravir in patients with Ebola virus disease: early results of the JIKI trial in Guinea. Abstract 103-ALB. 22nd Conference on Retroviruses and Opportunistic Infections, pp.23-26, 2015.
,
Maximum likelihood estimation in nonlinear mixed effects models, Comput Stat Data Anal, vol.49, pp.1020-1038, 2005. ,
Centers for Disease Control and Prevention. Ebola transmission linked to a single traditional funeral ceremony-Kissidougou, Guinea, MMWR Morb Mortal Wkly Rep, vol.64, p.25879897, 2014. ,
Are adaptive randomised trials or non-randomised studies the best way to address the Ebola outbreak in west Africa?, Lancet Infect Dis, vol.15, pp.738-745, 2015. ,
Evaluating novel therapies during the Ebola epidemic, JAMA, vol.312, pp.1299-1300, 2014. ,
An open-label, multicenter study of the safety and anti viral activity of brincidofovir (BCV, CMX001) for Ebola virus disease, ClinicalTrials.gov, 2014. ,
Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea, N Engl J Med, vol.374, issue.1, pp.33-42, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01252702
, Putative investigational therapeutics in the treatment of patients with known Ebola infection, ClinicalTrials.gov, 2015.
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.514, pp.47-53, 2014. ,
Evaluating clinical trial designs for investigational treatments of Ebola virus disease, PLoS Med, vol.12, p.25874579, 2015. ,
Randomised controlled trials for Ebola: practical and ethical issues, Lancet, vol.384, issue.14, p.25390318, 2014. ,
Analysis of human peripheral blood samples from fatal and nonfatal cases of Ebola (Sudan) hemorrhagic fever: cellular responses, virus load, and nitric oxide levels, J Virol, vol.78, p.15367603, 2004. ,
Ebola hemorrhagic fever: novel biomarker correlates of clinical outcome, J Infect Dis, vol.210, pp.558-566, 2014. ,
The contribution of Ebola viral load at admission and other patient characteristics to mortality in a Medecins Sans Frontieres Ebola case management centre, J Infect Dis, vol.212, pp.1752-1758, 2014. ,
Clinical presentation, biochemical, and haematological parameters and their association with outcome in patients with Ebola virus disease: an observational cohort study, Lancet Infect Dis, vol.15, issue.15, p.26271406, 2015. ,
Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report, Lancet Infect Dis, vol.15, pp.1034-1040, 2015. ,
Severe sepsis and septic shock, N Engl J Med, vol.369, pp.840-851, 2013. ,
Acute kidney injury, Lancet, vol.380, issue.11, p.22617274, 2012. ,
Bacterial, fungal, parasitic, and viral myositis, Clin Microbiol Rev, vol.21, pp.473-494, 2008. ,
DOI : 10.1128/cmr.00001-08
URL : https://cmr.asm.org/content/21/3/473.full.pdf
Tumor necrosis factor and coxsackie B4 rhabdomyolysis, Ann Intern Med, vol.119, p.861, 1993. ,
DOI : 10.7326/0003-4819-119-8-199310150-00024
Sporadic viral myositis in two adults, CMAJ, vol.137, p.2832046, 1987. ,
Rhabdomyolysis and acute kidney injury, N Engl J Med, vol.361, pp.62-72, 2009. ,
, Experimental Treatment with Favipiravir for Ebola Virus Disease, PLOS Medicine, 2016.
Filoviral immune evasion mechanisms, Viruses, vol.3, pp.1634-1649, 2011. ,
DOI : 10.3390/v3091634
URL : https://www.mdpi.com/1999-4915/3/9/1634/pdf
Structural basis for Marburg virus VP35-mediated immune evasion mechanisms, Proc Natl Acad Sci U S A, vol.109, pp.20661-20666, 2012. ,
ReEBOV Antigen Rapid Test kit for point-of-care and laboratory-based testing for Ebola virus disease: a field validation study, Lancet, vol.386, pp.867-874, 2015. ,
Alterations in favipiravir (T705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, pp.132-137, 2015. ,
Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock, Crit Care Clin, vol.27, pp.19-34, 2011. ,